The selective cyclooxygenase 2 (COX-2) inhibitor celecoxib is no more likely than 2 nonsteroidal anti-inflammatory drugs (NSAIDs) to cause cardiovascular death, nonfatal myocardial infarction, or stroke in patients with coronary disease or other cardiovascular risks.
The US Food and Drug Administration required the postmarketing safety trial, sponsored by Pfizer, which makes the only selective COX-2 inhibitor still available, over concerns that the drug might have adverse cardiovascular effects similar to those found with rofecoxib, withdrawn in 2004. The trial also did not support the widely held belief that naproxen is cardioprotective.
Anita Slomski. Celecoxib Similar to 2 NSAIDs for Cardiovascular Safety. JAMA. 2016;316(24):2589. doi:10.1001/jama.2016.19355